Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized CBT for Pts With High-risk Hematologic Malignancies Who Have Relapsed After First ASCT
NCT06807606Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Orthosteric Ligands, RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, fludarabine, thiotepa, tacrolimus and mycophenolate mofetil in hematologic malignancy, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival at 1 year and Safety and Adverse Events at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
cyclophosphamidefludarabinethiotepatacrolimusmycophenolate mofetil
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT06807606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807606.